Eli Lilly And Co vs VanEck Semiconductor ETF — how do they compare? Eli Lilly And Co trades at $1,221.01 (market cap $1.08T), while VanEck Semiconductor ETF trades at $585.97. The key difference: Eli Lilly And Co pays a 0.57% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals.
| LLY | SMH | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | — |
52-Week High | $1.24K | $668.91 |
52-Week Low | $639.43 | $286.43 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
SMH trades at $584.83, up 2.71% with a neutral technical signal. Moving averages show bullish momentum while oscillators indicate neutral conditions. Recent institutional activity includes Ferguson Shapiro's $4.53 million investment and Clark Asset Management's 105.8% stake increase. The ETF faces competition from alternative semiconductor funds like CHPY, which some analysts favor for income generation.
Outlook remains balanced with AI spending driving semiconductor demand but increasing competition and tariff risks. The fund's heavy Nvidia concentration presents both opportunity and volatility risk. Technical resistance at $587 could limit near-term gains while support at $560 provides downside protection.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →